Investor Relations

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition more »

Conversion Right Extended on OPKO 3.0% Convertible Senior Notes more »

OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection more »

OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress on Its Long-Acting Clotting Factor VIIa more »

Investor FAQs